Role of angiogenesis related genes and their mutations in the development of renal carcinoma

A tétel rövid nézete
dc.contributor.advisorSzabó, Zsuzsanna
dc.contributor.advisorHalmos, Gábor
dc.contributor.advisordeptDebreceni Egyetem::Gyógyszerésztudományi Kar::Biofarmácia Tanszékhu_HU
dc.contributor.authorZargarzadeh, Ghazal
dc.contributor.departmentDE--Gyógyszerésztudományi Karhu_HU
dc.contributor.opponentZöld, Éva
dc.contributor.opponentSzegedi, Krisztián
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Belgyógyászati Intézethu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Urológiai Klinikahu_HU
dc.date.accessioned2018-05-16T08:11:37Z
dc.date.available2018-05-16T08:11:37Z
dc.date.created2018-03-08
dc.description.abstractRenal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and accounts for >90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear cell RCC (ccRCC) is most common and accounts for most cancer-related deaths. Although somatic Von Hippel–Lindau (VHL) mutations have been described for some time, more-recent cancer genomic studies have identified mutations in epigenetic regulatory genes and demonstrated marked intra-tumour heterogeneity, which could have prognostic, predictive and therapeutic relevance. Localized RCC can be successfully managed with surgery, whereas metastatic RCC is refractory to conventional chemotherapy. However, over the past decade, marked advances in the treatment of metastatic RCC have been made, with targeted agents including sorafenib, sunitinib, bevacizumab, pazopanib and axitinib, which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGFR), and everolimus and temsirolimus, which inhibit mechanistic target of rapamycin complex 1 (mTORC1), being approved.hu_HU
dc.description.correctorgj
dc.description.coursegyógyszerészhu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent36hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/252265
dc.language.isoenhu_HU
dc.subjectAngiogenesishu_HU
dc.subjectRenal cell carcinomahu_HU
dc.subjectPTENhu_HU
dc.subjectVHLhu_HU
dc.subjectmutationhu_HU
dc.subject.dspaceDEENK Témalista::Orvostudomány::Gyógyszerésztudományhu_HU
dc.titleRole of angiogenesis related genes and their mutations in the development of renal carcinomahu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Pharmacy)